Maintenance
Long-term maintenance — what happens after reaching goal weight, whether to continue, reduce dose, or stop — is an increasingly active discussion as early community members reach their targets. This page examines the evidence on long-term use and discontinuation.
Maintenance decisions require physician oversight. TRIUMPH-Maintenance trial data will provide the most rigorous evidence on this question; results are pending.
Common Claims — Fact-Checked
These claims appear frequently in community discussions. Each is evaluated against the best available clinical evidence.
"You can stop retatrutide once you reach your goal weight."
?Context NeededDiscontinuation data from GLP-1 class agents consistently shows weight regain after stopping. TRIUMPH-Maintenance is specifically designed to answer this question for retatrutide. Based on class evidence, most patients regain substantial weight within 1–2 years of discontinuation.
"A lower maintenance dose is enough to keep the weight off."
?Insufficient EvidenceDose reduction after reaching goal weight is a reasonable hypothesis but is not validated for retatrutide. TRIUMPH-Maintenance will provide data. For other GLP-1 agents, dose reduction is associated with partial weight regain.
Evidence Summary
TRIUMPH-Maintenance trial is ongoing. Class evidence from semaglutide (STEP 4 trial) shows ~7% weight regain within 1 year of discontinuation, with continued regain thereafter. Retatrutide's glucagon receptor component may affect long-term metabolic set point differently, but this is speculative.
Analyzed Threads
These threads were selected for editorial analysis. TryTrutide does not link to Reddit posts.
"Hit a wall at 12 weeks — is this normal or is my dose too low?"
✓SupportedClaim: Many users report a weight loss plateau around weeks 10–14, often at doses of 4–8 mg, and ask whether this is a sign they need to escalate dose or whether it is a normal physiological response.
Weight loss plateaus during GLP-1/GIP/glucagon agonist therapy are well-documented and physiologically expected. The body adapts to reduced caloric intake through metabolic adaptation (reduced resting energy expenditure) and increased appetite signaling. In the TRIUMPH-Obesity Phase 3 trial, the weight loss curve shows a characteristic deceleration after the initial rapid phase, with continued but slower loss through week 48. Dose escalation from 4 mg to 8 mg or 8 mg to 12 mg typically produces a renewed weight loss response. The community observation is consistent with the clinical data.
Reddit Observatory
26 topic categories — community claims vs. clinical evidence
Want a Physician to Review Your Eligibility?
Retatrutide is not yet FDA approved. A physician can review your health profile and discuss investigational access options.
Start Physician Review